Starting in 2022, manufacturers didn’t have enough supply of injectable GLP-1 (glucagon-like peptide-1) medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) in order to keep pace with demand.
In late 2024, the FDA indicated that the tirzepatide injection shortage was over, and in early 2025, the semaglutide injection shortage was also resolved.
In this video, learn what this means for the availability of compounded GLP-1 medications, according to Stacia Woodcock, PharmD, Pharmacy Editor at GoodRx.
Search and compare options
Stacia Woodcock, PharmD, is a pharmacy editor for GoodRx. She earned her Doctor of Pharmacy degree from the University of Kentucky and is licensed in New York and Massachusetts.
References
U.S. Department of Health and Human Services, et al. (2018). Compounded drug products that are essentially copies of a commercially available drug product under section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for industry.
U.S. Food and Drug Administration. (2024). Compounding when drugs are on FDA’s Drug Shortages List.
U.S. Food and Drug Administration. (2024). 7 things to know about drug shortage management.
U.S. Food and Drug Administration. (2025). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
Why trust our experts?
